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Broadly neutralizing antibodies (bNAbs) to HIV-1 can
prevent infection and are therefore of great impor-
tance for HIV-1 vaccine design. Notably, bNAbs
are highly somatically mutated and generated by
a fraction of HIV-1-infected individuals several years
after infection. Antibodies typically accumulate
mutations in the complementarity determining
region (CDR) loops, which usually contact the
antigen. The CDR loops are scaffolded by canonical
framework regions (FWRs) that are both resistant to
and less tolerant of mutations. Here, we report that
in contrast to most antibodies, including those with
limited HIV-1 neutralizing activity, most bNAbs
require somatic mutations in their FWRs. Structural
and functional analyses reveal that somatic muta-
tions in FWR residues enhance breadth and potency
by providing increased flexibility and/or direct
antigen contact. Thus, in bNAbs, FWRs play an
essential role beyond scaffolding the CDR loops
and their unusual contribution to potency and
breadth should be considered in HIV-1 vaccine
design.126 Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc.INTRODUCTION
A fraction of HIV-1-infected individuals mount a broadly neutral-
izing serologic response (Doria-Rose et al., 2010; Simek et al.,
2009) 2–3 years after infection (Mikell et al., 2011). Antibodies
generated by these individuals are of great interest for vaccine
design because they can protect macaques from infection (Mas-
cola et al., 2000; Moldt et al., 2012; Shibata et al., 1999). More-
over, combinations of broadly neutralizing antibodies can control
an established HIV-1 infection in humanized mice (Klein et al.,
2012b).
Despite their potential importance to vaccine development
and HIV-1 therapy, little was known about the molecular compo-
sition of the human anti-HIV-1 antibody response until single-cell
antibody cloning techniques were developed and used for
characterizing IgGs from the sera of HIV-1-infected individuals
with broadly neutralizing activity (Scheid et al., 2009a; Scheid
et al., 2009b). This analysis revealed highly potent bNAbs, all
of which might eventually be used in vaccine development
(Corti et al., 2010; Huang et al., 2012; Morris et al., 2011; Mou-
quet et al., 2012; Scheid et al., 2011; Walker et al., 2009,
2011b; Wu et al., 2010).
A surprising observation was that anti-HIV-1 antibodies are
highly somatically mutated when compared to other immuno-
globulins (IgGs) cloned from the same patients (Scheid et al.,
2009a; Xiao et al., 2009a, 2009b). Whereas most human
antibodies that have undergone affinity maturation carry 15–20
VH-gene somatic mutations (Tiller et al., 2007), potent broadly
neutralizing antibodies carry 40–100 VH-gene mutations (Corti
et al., 2010; Scheid et al., 2011; Walker et al., 2009, 2011b; Wu
et al., 2010; Xiao et al., 2009a, 2009b). These mutations are
essential because reversion to the antibody germline sequence
drastically reduces neutralizing potency and breadth (Mouquet
et al., 2010; Scheid et al., 2011; Wu et al., 2011; Xiao et al.,
2009b; Zhou et al., 2010). However, why so many mutations
appear to be required is not known.
Wu and Kabat first divided antibody variable regions into
complementarity determining regions (CDRs) and framework
regions (FWRs) based on the number of somatic hypermutations
in these regions (Wu and Kabat, 1970) (Figures 1A and 1B). The
CDRs consist primarily of loops that form the sites of contact
between the antibody and antigen (Amzel and Poljak, 1979)
and account for the specificities of most antibody molecules
as demonstrated by CDR grafting experiments (Jones et al.,
1986). The structural integrity of the variable domains is main-
tained by the FWRs, which encode nine antiparallel b strands
arranged into two b sheets (one sheet containing strands A, B,
E, and D and the other containing strands C,’’ C’, C, F and G;
Figures 1A and 1B). The relatively invariant b strands of the
FWRs serve as a scaffold for three CDR loops, which connect
strands B and C, C’ and C,’’ and F and G (Figures 1A and 1B)
(Amzel and Poljak, 1979).
Somatic mutations are preferentially found in the CDR loops
where they can alter the antibody combining site without
affecting the overall structure of the variable domain (Wu and Ka-
bat, 1970). Mutations in the FWR are usually poorly tolerated and
generally biased to neutral substitutions to avoid changes that
would destroy the structural underpinnings of the variable
domain (Reynaud et al., 1995; Wagner et al., 1995).
Here we examine the role of somatic mutations in the devel-
opment of broadly neutralizing anti-HIV-1 antibodies. In con-
trast to most other antibodies, including anti-HIV-1 antibodies
with limited neutralization activity, we found that FWR muta-
tions, including noncontact residues, are essential for the
neutralizing activity of most potent bNAbs. We propose that
the requirement to alter the FWR, without destroying its essen-
tial structural elements, accounts for the high mutation load
found in broadly neutralizing anti-HIV-1 antibodies and possibly
for the difficulty and prolonged latency with which such anti-
bodies develop.
RESULTS
SomaticHypermutation inHIV-1-NeutralizingAntibodies
To examine the role of somatic hypermutations in anti-HIV-1
antibody neutralization breadth and potency, we selected
a group of 9 HIV-1-reactive antibodies with activity limited to
easy to neutralize (Tier 1) HIV-1 strains (Seaman et al., 2010),
and 17 antibodies with broad neutralization activity (Figures 1C
and S1 and Table S1 available online). The antibodies with
limited neutralizing activity included antibodies recognizing the
CD4-binding site (CD4bs; 6-187, 9–913, and 11–989) (Mouquet
et al., 2011; Scheid et al., 2009a), the core epitope (1–479, 2–
491, and 11–591) (Mouquet et al., 2011; Pietzsch et al., 2010;Scheid et al., 2009a), the V3-loop (447-52D and 10–188) (Gorny
et al., 1993; Mouquet et al., 2011), and the CD4-induced site
(17b) (Thali et al., 1993) (Table S1). Eight of the 17 bNAbs also
recognize the CD4bs (VRC01, NIH45-46, 3BNC60, 12A12,
1NC9, 8ANC131, 12A21, and 3BNC117) (Scheid et al., 2011;
Wu et al., 2010), whereas others recognized the V1/V2 loop
(PG16) (Walker et al., 2009), carbohydrates (2G12) (Calarese
et al., 2003; Trkola et al., 1996), the core epitope (HJ16) (Corti
et al., 2010), the base of the V3-loop (10-1074 and PGT128)
(Mouquet et al., 2012; Walker et al., 2011a), the membrane
proximal external region (MPER; 4E10 and 2F5) (Buchacher
et al., 1994; Muster et al., 1993) and two antibodies (3BC176
and 8ANC195) (Klein et al., 2012a; Scheid et al., 2011) for
which the precise epitopes are not yet determined (Figure 1C
and Table S1).
Antibodies with limited neutralizing activity differ from bNAbs
in that they generally carry fewer somatic mutations (Figures
1C and S1 and Table S1). We used the well-accepted Kabat
system (Wu and Kabat, 1970) that utilizes sequence compari-
sons for FWR/CDR assignments. However, direct comparisons
between Kabat and the IMGT numbering system (Giudicelli
et al., 2006) (Figure 1B), which includes antibody structural
data, were also performed for a subset of antibodies.
Complete reversion of somatic mutations in the heavy and
light chain V genes (FWR1-3 and CDR1/2) drastically reduces
anti-HIV-1 antibody binding and neutralization activity (Bu-
chacher et al., 1994; Mouquet et al., 2010; Scheid et al., 2011;
Xiao et al., 2009b; Zhou et al., 2010). Moreover, reverting only
the CDR1 and CDR2 in 3BNC60 and NIH45-46 strongly dimin-
ished binding and neutralization (Figure S2A and Data S1A). To
determine the functional consequences of FWR mutations, we
reverted the framework residues to their germline counterparts
(FWR-GL) in each of the 26 selected antibodies (Data S1B–1D)
and evaluated binding to the HIV-1 envelope protein as well as
their neutralization activities.
HIV-1-Reactive Antibodies with Limited Activity
As expected, reversion of somatic mutations in the FWR resi-
dues (FWR-GL) of the HIV-1 antibodies with limited breadth
had only minimal effects on binding of most of these antibodies
to gp140YU2 (Figure S2B) as measured by ELISA and confirmed
by surface plasmon resonance (SPR) (data not shown). Only two
of these FWR-GL antibodies (9-913 and 10-188) showed
a decrease in binding (Figure S2B). In agreement with the ELISA
and SPR experiments, we found little or no change in neutralizing
activity in most of the FWR-GL antibodies with limited neutraliza-
tion activity on a panel of up to six Tier 1 viruses representing
clades A, B, and C (Figure S2B and Table S2). Only antibodies
9-913 and 10-188, which displayed decreased binding to
gp140YU2, showed a decrease (9-913) or complete loss (10-
188) in neutralizing activity (Figure S2B and Table S2). We
conclude that with two exceptions out of nine antibodies tested,
FWR mutations do not alter the binding or neutralizing activity of
anti-HIV-1 antibodies with limited neutralizing activity. Thus,
despite their significantly higher levels of somatic mutation,
HIV-1-neutralizing antibodies with limited breadth resemble
previously characterized antibodies to other antigens in that
FWR mutations seem not to be essential.Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc. 127
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Figure 1. Somatic Mutations in the Framework Regions of HIV-1-Reactive Antibodies
(A) Ribbon representation of the variable domains of 3BNC60 (Scheid et al., 2011), illustrating the CDRs (magenta) and the FWRs of the immunoglobulin heavy
(blue) and light (cyan) chain.
(B) Illustration of Kabat and IMGT CDR (magenta) and FWR (IgH, blue; IgL, cyan) assignments for the variable heavy and light chain domains of 3BNC60. Gray
arrows indicate b strands defined by the crystal structure of the 3BNC60 Fab (Scheid et al., 2011).
(C) Position of FWR mutations in heavy and light chain of the 17 investigated antibodies with broad neutralizing activity (see also Data S1). Indicated are silent
(black) and replacement (red) mutations. Insertions are illustrated in blue. For mAbs 2G12, 2F5, and 4E10, only amino acid replacements are shown (red). Number
of replacement mutations within CDR1/2 and FWR1-4 are listed in the two columns at the very right (see also Table S1). HIV-1-reactive antibodies with limited
neutralization are displayed in Figure S1.Potent Broadly Neutralizing Antibodies
In contrast, reversion of the FWR mutations in most of the
17 broadly neutralizing antibodies decreased their binding to
gp140YU2 (Figures 2 and3). Threeof the antibodies, PG16 (Walker128 Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc.et al., 2009), 8ANC195 (Scheid et al., 2011), and 3BC176
(Klein et al., 2012a) bound poorly to gp140YU2 when measured
up to 8 mg/ml and differences in binding between mutated
and reverted antibodies could not be evaluated (Figure 2).
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The neutralizing activity of the reverted antibodies was tested
on a panel of 11 viruses (Tier 1 to Tier 3) representing HIV-1
clades A, B, and C (Figures 2 and 3 and Table S2). The majority
of the FWR-GL antibodies lost nearly all their neutralizing activity
against the tested strains. Similar results were also obtained
when we produced FWR-GL antibody versions of VRC01,
3BNC60, and 8ANC131 according to IMGT alignment (Data
S1F and Figure S2C). 4E10, which is among the least potent anti-
bodies of the bNAbs tested, was the exception to the rule in re-
taining binding to gp140YU2 as well as potency and breadth.
PG16 retained most of its neutralizing breadth, but like the other
bANbs, it lost potency by at least 10-fold after FWR reversion
(geometric mean IC50 values increased from 0.95 to 9.69, Fig-
ure 2 and Table S2). 2G12 represents a special case for interpret-
ing the effects of FWR residue reversion because the two Fabs of
2G12 IgG form a domain-swapped (Fab)2 unit that creates
a single antigen-binding site for recognizing a constellation of
host-derived high mannose carbohydrates on gp120 (Calarese
et al., 2003) (Figure S3). FWR residues are critical for the Fab
dimerization via domain swapping (Huber et al., 2010) as well
as for formation of a novel carbohydrate-binding site at the VH-
VH’ interface (Calarese et al., 2003).
To provide a general understanding of the relationship
between direct FWR contacts and CDRH3 length on the degree
of FWR somatic mutation, we analyzed these parameters for
bNAbs for which antibody-antigen structures have been deter-
mined. No correlation was observed with CDRH3 length and
degree of heavy chain, light chain, or total amount of FWR
somatic mutation (Figure S4). Notably, however, the FWR
contact surface area with antigen did correlate with the total
number of amino acid changes in FWRs (Figure S4; p value =
0.0088; rho = 0.533).
To determine whether the effects of FWR reversion on binding
and neutralization were simply due to alterations in contact resi-
dues, we selectively reverted all mutated FWR residues except
for the contact residues (FWR-GLCR+; Figure 3) in four bNAbs
whose contact residues were known (VRC01, NIH45-46,
12A21, and 3BNC117) (Scheid et al., 2011; Wu et al., 2011;
Zhou et al., 2010; unpublished data). Despite retaining their
FWR contact residues, all of the partially reverted antibodies
showed lower levels of binding by ELISA and SPR. Interestingly,
the SPR-binding curves showed that loss of affinity appeared to
be primarily due to an increased dissociation rate (off rate; kd)
(Figure 3). We conclude that FWRmutations enhance the affinity
of broadly neutralizing antibodies primarily by decreasing the
dissociation rate. Most importantly, FWR-GLCR+ antibodies
that retained somatically mutated FWR contact residues lost
both neutralizing breadth and potency (Figure 3 and Table S2).Figure 2. Binding and Neutralization Activity of Mature and FWR-Reve
Evaluation of binding to gp140YU2 ELISA (left) of mature antibodies (green) and an
the right compare IC50 values for neutralization of Tier 1 (MW965.26, SF162.LS
TRO.11, and YU2.DG), and Tier 3 (PVO.4) viruses (Table S2). Only viruses are sho
activity is color coded (blue arrow, <0.001 mg/ml; dark red, IC50 between 0.001
1–10 mg/ml; yellow, >10 mg/ml; white, IC50 was not achieved up to the tested conc
in Figure S2A and HIV-1-reactive antibodies with limited neutralization are displ
reverted according to IMGT (Giudicelli et al., 2006) and results are shown in F
Figure S3.
130 Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc.We conclude that FWR mutations in noncontact residues are
essential for the binding, breadth, and potency of most broadly
neutralizing anti-HIV-1 antibodies.
Importance of a FWR Insertion in 3BNC60
Insertions and deletions are infrequent byproducts of somatic
hypermutation that occur as a result of double-strand DNA
breaks induced by deamination of neighboring cytidine residues
by activation-induced cytidine deaminase (AID) (Pavri and Nus-
senzweig, 2011; Wilson et al., 1998). Nevertheless, several
potent anti-CD4bs antibodies, including 3BNC60, contain inser-
tions within FWRs that are acquired during somatic mutation
(Scheid et al., 2011). Sequence analysis of the clonal relatives
of 3BNC60 (clone RU01) revealed a correlation between the
presence of this insertion and neutralizing activity (Figure 4).
Superimposition of the 3BNC60 Fab structure onto the Fab
portion of the NIH45-46/gp120 complex structure (Diskin et al.,
2011) suggested that this insertion might enhance binding
by interacting with the V1/V2 loop region that was truncated in
the gp120 construct that was crystallized (Figure 5A) (similar
results were found when superimposing the 3BNC60 Fab onto
the 3BNC117 Fab, two nearly identical antibodies, in the
3BNC117/gp120 cocrystal structure [unpublished data]). To
assess the effects of the insertion within FWR3 of the 3BNC60
heavy chain, we constructed a 3BNC60 mutant (3BNC60DI)
in which the Trp-Asp-Phe-Asp insertion was removed (Fig-
ure 5B) and evaluated its neutralization activity against a panel
of seven viruses chosen to include strains that were resistant
to VRC01 but sensitive to 3BNC60 (Figure 5C). 3BNC60DI lost
neutralization potency against all seven viruses. Adding the
insertion to 3BNC55, a weaker variant of 3BNC60 isolated
from the same donor (Scheid et al., 2011), increased the neutral-
ization potency of 3BNC55+I compared to 3BNC55 against one
viral strain (TRO.11) (Figure 5C). Addition of the insertion did
not, however, restore the ability of a VRC01 plus insertionmutant
to neutralize VRC01-resistant viruses (Data S1E and Table S2).
Taken together, these results demonstrate that the FWR inser-
tion is critical for the neutralization activity of 3BNC60, but that
its ability to improve potency requires a precise recognition
geometry that is not always found in other potent anti-CD4bs
antibodies.
Crystal Structure of a Partially Reverted Fab
We previously noted a disruption in the canonical variable
domain fold of the VH domain of 3BNC60 (Scheid et al., 2011);
namely, the main chain hydrogen bonding pattern between
strands C’’ and C’ was disrupted by the presence of Pro61
(Kabat numbering position 60; IMGT position 68) located at therted (FWR-GL) Broadly Neutralizing Antibodies
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Figure 3. Binding and Neutralization Activity of Mature, FWR-GL, and FWR-GLCR+ Broadly Neutralizing Antibodies
Evaluation of binding to gp140YU2 ELISA (left) and SPR (middle) of mature antibodies (green), antibodies with FWRs reverted to germline (FWR-GL, blue), and
antibodies with germline-reverted FWRs except gp120-contacting residues (FWR-GLCR+; light blue; Data S1D). SPR results are shown for starting concentrations
of 1 mM. BD (below detection; no binding of the antibody was observed). Panels on the right compare IC50 values for neutralization of Tier 1 to Tier 3 viruses (Table
S2) as in Figure 2. Neutralization activity is color coded as indicated.C-terminal end of strand C’’ (Figure 6A). In contrast, the germline
VH sequence and other potent anti-CD4bs antibodies contain an
alanine at this position (Scheid et al., 2011) (Data S1C and S1D).
A proline within a b strand cannot form a main chain hydrogen
bond with a carbonyl oxygen in an adjacent b strand because
it lacks a hydrogen atom attached to its mainchain nitrogen
(Figure 6A). Nevertheless, this proline mutation is associatedwith increased antibody potency among clonal members of the
3BNC60 family (Figure 4) (Scheid et al., 2011).
Although classified by Kabat (Kabat et al., 1991) as part of
CDRH2, residue 61 is within the C’’ b strand of the Ig V domain
fold and is classified as a FWR residue by IMGT (Lefranc et al.,
1999) (Figure 1B, S5). Thus we were interested in its potential
role in antigen recognition. In the structure of the free 3BNC60Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc. 131
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Figure 4. Effects of a FWR Insertion and
a C’’ b Strand Proline in Clone RU01
Phylogenetic tree of the antibodies (Ig heavy chain)
derived from the RU01 clone that members
include 3BNC117 and 3BNC60 (Scheid et al.,
2011). Antibodies that carry both the four amino
acid insertion in FWR3 and the A61P somatic
mutation are shown in red, antibodies with only the
A61P mutation are shown in orange, and anti-
bodies without either feature are shown in black.
Bootstrap values (1,000 trials, seed = 111) of the
phylogenetic tree are indicated. Structure of
3BNC117 IGVH in its gp120-bound conformation
is shown in Figure S5.Fab, the region surrounding Pro61 is stabilized by a crystal
contact (Figure S6) into a position that would clash with the
CD4-binding loop of gp120 (Diskin et al., 2011; Scheid et al.,
2011; Wu et al., 2011; Zhou et al., 2010). The potential clash
with gp120 suggests that the region surrounding 3BNC60
Pro61 rearranges upon gp120 binding. Indeed, in the structure
of a gp120 complex with the nearly identical antibody
3BNC117, the Fab exhibits a canonical VH domain structure in
its gp120-bound conformation (unpublished data) (Figure 6A).
In addition, a murine Fab structure including a proline at this
position showsminimal disruption of the b sheet including strand
C’’ (Stanfield et al., 1990) (Figure 6A).
To address the unusual properties of the C’’ strand in 3BNC60,
we solved the 2.65 A˚ crystal structure of 3BNC60P61A (pdb code
4GW4), a single amino acid revertant mutant form of 3BNC60
(Figure 6A and Table S3). Like other Fabs containing alanine at
position 61, including VRC01 (Zhou et al., 2010), VRC03, VRC-
PG04 (Wu et al., 2011) and NIH45-46 (Diskin et al., 2011; Scheid
et al., 2011), strand C’’ of 3BNC60P61A Fab exhibited normal
hydrogen bonding to the neighboring C’ strand (Figure 6A).
Although the displaced region of strand C’’ in the 3BNC60 Fab
was involved in interactions with a crystallographic neighbor,
perhaps stabilizing it in the conformation observed in the struc-
ture (Scheid et al., 2011), the corresponding region of strand
C’’ in the 3BNC60P61A Fab did not contact a crystallographic
neighbor despite isomorphous packing interactions in the
3BNC60 and 3BNC60P61A crystals (Figure S6).
To further evaluate the effects of the Pro to Ala substitution in
strand C,’’ we compared the thermal stability of the 3BNC60 and
3BNC60P61A Fabs (Figure 6B). Both proteins exhibited denatur-
ation profiles characteristic of two-state (native to denatured) un-
folding; however, the 3BNC60P61A Fab showed increased
thermal stability compared with the wild-type 3BNC60 Fab, as
demonstrated by a higher transition midpoint (Tm) (Figure 6B).
The functional consequences of the Pro to Ala substitution
were evaluated by comparing the neutralization potencies of
3BNC60 and 3BNC60P61A IgGs against 19 representative strains
sensitive to 3BNC60 (Figure 6C). The substitution affected the
neutralizing activity of the antibody against seven of the strains
(highlighted red; Figure 6C). We conclude that somatic mutation
in the b sheet framework involving strand C’’ is essential for the
potency and breadth of 3BN60.132 Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc.DISCUSSION
The b sandwich structure of the immunoglobulin fold lends itself
to a natural division into relatively structurally invariant b strand
FWRs and the more structurally diverse loops connecting the
b strands, three of which form the hypervariable CDRs (Figures
1A and 1B). Thus, mutations in FWRs are usually poorly tolerated
and selected against, whereas mutations in the structurally
diverse CDRs are well tolerated. Starting with the first crystal
structure of a Fab bound to a protein antigen (Amit et al.,
1986), antibody-antigen complex structures have confirmed
that residues within the CDR loops usually form the majority of
contacts with the antigen. Therefore the primary role of FWR
residues is to provide a scaffold for the antigen-contacting
CDRs, as evidenced by the common practice of CDR grafting
(Jones et al., 1986). However, we find that in contrast to most
antibodies, including HIV-1-reactive antibodies with limited
neutralizing activity (Figures S1 and S2B), somatically mutated
FWR residues are critical for the breadth and potency of broadly
neutralizing anti-HIV-1 antibodies (Figure 2 are 3). Thus, the
FWRs in these unusual antibodies serve an essential function
beyond that of a scaffold for antigen-binding CDRs.
Understanding the excessive somatic hypermutation found in
bNAbs requires consideration of the process by which anti-
bodies are mutated. B cells undergo somatic hypermutation in
germinal centers during T-cell-dependent immune responses
(Victora and Nussenzweig, 2012). The mutations are introduced
by AID, which preferentially targets cytosines embedded in
RGYW nucleotide sequences (in which R can be A or G, Y can
beC or T, andWcan be A or T) in antibody variable regions (Pavri
and Nussenzweig, 2011). However, mutations are not limited to
cytidine residues because error prone repair mechanisms also
contribute to the repair of the initial lesions (Pavri and Nussenz-
weig, 2011; Peled et al., 2008). Thus, the mutation process is far
more random than would occur if only RGYW cytidines were
targeted.
Mutations that enhance antibody affinity are rare, but they are
positively selected in the germinal center as a result of increased
antigen uptake and MHC-peptide presentation, which results in
increased T-cell-mediated help (Victora and Nussenzweig,
2012). Mutations that increase antibody affinity can do so by
increasing the on-rate or by decreasing the off rate. The on-rate
A B
C
Figure 5. Analysis of 3BNC60 Insertion
(A) Superimposition of the structure of the VH domain of 3BNC60 (cyan) (Scheid et al., 2011) onto the NIH45-46 VH domain from cocrystal structure of NIH45-46
(gray) bound to gp120 (gold) (Diskin et al., 2011) highlighting the four residue insertion in FWR3 of 3BNC60 (cyan arrow) and a potential interaction between the
insertion and the gp120 V1/V2 loop (note that the V1/V2 loop was truncated in the gp120 construct used for cocrystallization with NIH45-46 and VRC01) (Diskin
et al., 2011; Zhou et al., 2010).
(B) Alignment of the heavy chain FWR3 sequences of 3BNC60 (Scheid et al., 2011), 3BNC60 without the 3BNC60 insertion (3BNC60DI), 3BNC55 (Scheid et al.,
2011), and 3BNC55 containing the 3BNC60 insertion (3BNC55+I; Data S1E). The four amino acid insertion in FWR3 of 3BNC60 is shown in cyan and the region
grafted into 3BNC60 from 3BNC55 in order to delete the insertion without disrupting the structure is shown in gray. The amino acid changes to introduce the
insertion into 3BNC55 are shown in blue.
(C) In vitro neutralization data (IC50 values in mg/ml) comparing the potencies of the antibodies. The upper panel compares neutralization of selected viral strains by
3BNC60 and 3BNC60DI. The lower panel compares the neutralization by a less potent member of the RU01 clone (3BNC55), in which the FWR3 insertion of
3BNC60 was introduced (3BNC55+I). Reduced and increased neutralization activity of the engineered antibodies (3BNC60DI, 3BNC55+I) is highlighted red and
green, respectively. Neutralization data on VRC01 with and without the 3BNC60 insertion is displayed in Table S2.is diffusion limited, and the off rate is limited by speed of antigen
internalization because once the antigen is in a degradative en-
dosome it will be digested irrespective of its rate of release
from the antibody (Batista and Neuberger, 1998; Foote and
Milstein, 1991). Thus, naturally developing antibody affinities
do not normally exceed an affinity of 1011 M. In humans, this
degree of affinity maturation is usually achieved with an average
of 10–15 nucleotide mutations focused in the antigen contact
residues in the CDR loops.
Although somatic mutations occur throughout the variable
region, mutations that alter the amino acid coding sequence of
the antibody accumulate preferentially in CDRs in part because
of higher level of degeneracy of the codons used in the FWRs
(Jolly et al., 1996; Reynaud et al., 1995; Wagner et al., 1995).
Any alterations in the FWRs are constrained by the fact that
theymust conserve the overall structure of the antibody because
B cells that fail to express surface Ig are destined to die by
apoptosis (Rajewsky, 1996). Indeed the FWRs appear to have
evolved a nucleotide coding sequence that resists mutation in
order to prevent changes in relatively invariant b strands that
are required to scaffold the CDR loops (Jolly et al., 1996;
Reynaud et al., 1995; Wagner et al., 1995). Thus, a large
number of random nucleotide mutations would be required to
alter the FWRs in a manner that optimizes the broadly neutral-izing anti-HIV-1 antibodies while conserving essential structural
elements.
The mutated FWR residues in the broadly neutralizing anti-
HIV-1 antibodies contribute to binding and enhance breadth
and potency in several different ways. In some cases, the
substituted FWR residues directly contact the antigen; for
example, crystal structures of the bNAbs VRC01 and NIH45-46
complexed with gp120 (Diskin et al., 2011; Zhou et al., 2010)
reveal that FWR residue Arg71 in both VRC01 and NIH45-46
forms a salt bridge with gp120 residue Asp368. Thus, FWR
mutation can serve to directly increase the binding interface by
recruiting portions of the antibody that are not normally involved
in antigen recognition. Moreover the ligand-bound structure of
PGT128 (Pejchal et al., 2011) shows that the carbohydrate
attached to Asn121gp120 interacts with residues within the C’’
b strand of the antibody heavy chain (Trp56, Thr57, His59 and
Lys64). Two of these residues represent somatic mutations. In
other cases, FWR residues do not appear to directly contact
the antigen, yet are required for potency. For example, the
FWRs of PG16 do not contribute substantially to direct antigen
contacts and interaction with the antigen is mainly mediated
through a long CDR3 loop (unpublished data) (Figure S4).
Somatic mutation of residues within the b sheet framework of
the V domain can also indirectly affect the V domain structure soCell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc. 133
Figure 6. Comparison of 3BNC60 and 3BNC60P61A Structures, Thermal Denaturation Profiles, and Neutralizing Activities
(A) Left: 3BNC60P61A (Table S3; magenta, heavy chain; orange, light chain) was superimposed on the structure of 3BNC60 (cyan, heavy chain; red, light chain).
The C’’ b strand within FWR3 of the VH domain differs in conformation between the two structures. Middle/right: Close-up of the C’ and C’’ b strands of
3BNC60P61A (magenta), 3BNC117 bound to go120 (yellow), 3BNC60 (cyan), and amurine Fab (green). Themain chain atoms of the VH domain C’ andC’’ b strands
of 3BNC60P61A exhibit a typical hydrogen-bonding pattern for an antiparallel b sheet. Three of the five inter-b strand hydrogen bonds in 3BNC60P61A are found in
all three structures (yellow dashed lines), whereas 3BNC60 lacks two and the murine Fab/3BNC117 lacks one of the hydrogen bonds (green dashed lines in
3BNC60P61A). Cocrystallization of the 3BNC60-relative 3BNC117 with gp120 shows that Proline61 is accommodated without disrupting the C’-C’’ b sheet when
3BNC117 is bound to gp120. Overview of the packing in crystals of 3BNC60 and 3BNC60P61A is shown in Figure S6.
(B) Thermal denaturation profiles of the 3BNC60 and 3BNC60P61A Fabs monitored by the CD signal at 218 nm. Tms (indicated with arrows) were derived by
estimating the half-point of the ellipticity change between the beginning and end of each transition. Errors bars indicate SD.
(C) In vitro neutralization data (IC50 values in mg/ml) comparing the 3BNC60 and 3BNC60
P61A IgGs for a panel of 19 viruses. Reduced neutralization activity is
highlighted in red. An additional nine viral strains (T250-4, T278-50, 620345.c01, X2088_c9, 89-F1_2_25, 6540.v4.c1, CAP45.2.00.G3, 6545.v4.c1, and Du422.1)
were resistant to both 3BNC60 and 3BNC60P61A. The 3BNC60P61A mutant was not significantly more potent than 3BNC60 against any of the 28 strains tested.as to facilitate HIV-1 antigen recognition, as exemplified by the
Pro61 residue in the broadly neutralizing antibodies 3BNC60/
3BNC117 (Figure 6). Residue 61 falls within the b sheet frame-
work of the Ig V domain. Substitution of this proline to the germ-
line alanine in 3BNC60 resulted in increased thermal stability, but134 Cell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc.a loss of neutralization activity against some HIV-1 strains. The
structural effects of the proline to alanine substitution were
revealed by comparison of the crystal structures of the
3BNC60P61A and 3BNC60 Fabs: the VH domain b strand that
was disrupted by the proline in the 3BNC60 structure was
restored to its canonical position in the mutant Fab structure
(Figure 6A). In the 3BNC117/gp120 structure (unpublished
data), the Pro61-containing b strand is shifted from its position
in the free 3BNC60 structure (where it was likely stabilized into
the observed conformation by crystal packing forces) in order
to avoid clashing with the CD4-binding loop in gp120, as pre-
dicted previously for 3BNC60/gp120 complexes (Scheid et al.,
2011) (Figure 6A). The lower thermal stability of 3BNC60 Fab
compared with 3BNC60P61A Fab (Figure 6B) is consistent with
flexibility that would allow this sort of displacement.
Superimposition of the 3BNC60P61A Fab into the 3BNC117/
gp120 cocrystal structure (unpublished data) suggests that an
alanine would be accommodated equally as well as a proline
at position 61, and the fact that the P61A mutant of 3BNC60
neutralizes some HIV-1 strains equally as well as wild-type
3BNC60 suggests that Pro61 does not make any direct contacts
to HIV-1 gp120 that are critical for binding to gp120 and neutral-
ization. Instead we speculate that in the case of 3BNC60 and
3BNC117, the ability to disrupt the C’–C’’ portion of the
C’’C’CFG b sheet, which provides flexibility for VH residues 60–
66, is necessary in order to accommodate antigenic sequence
heterogeneity in or near the gp120 V5 loop. Taken together,
these results provide a counterintuitive example of a neutral or
functionally favorable somatic mutation that decreases the Fab
stability by disrupting the canonical VH domain fold, allowing
flexibility of the b sheet framework that is needed for optimal
antigen binding and neutralization (Figure 6C).
The high level of mutation found in broadly neutralizing anti-
bodies would be difficult to explain in the context of an immune
response to a conventional antigen and a single round of
germinal center selection. However, HIV-1 differs from conven-
tional antigens in that it presents the host with a continuously
evolving target that is selected on the basis of its ability to evade
the antibody response (Wei et al., 2003).We speculate that HIV-1
variants selected for their ability to evade antibodies due to low-
ered affinity will recall memory B cells to the germinal center for
additional rounds of mutation and selection. Thus, iterative
rounds of antibody mutation, selection, and viral escape would
facilitate the accumulation of essential mutations in the FWR
that conserve some key aspects of antibody structure while
altering others to enhance anti-HIV-1 breadth and potency.
In conclusion, our experiments suggest a molecular and
a structural rationale for the requirement of high levels of somatic
mutation found in broadly neutralizing antibodies and possibly
for the observation that it takes several years for infected individ-
uals to develop such antibodies. The high relevance of FWR
mutations should be considered in the approach to designing
an HIV-1 vaccine.EXPERIMENTAL PROCEDURES
Sequence Analysis of HIV-1-Reactive Antibodies
Analysis of heavy and light chain gene segment usage, number of somatic
mutations, and the presence of deletions or insertions was carried out using
the NCBI IgBLAST software (http://www.ncbi.nlm.nih.gov/igblast/). CDRs
and FWRs were designated according to the Kabat (Wu and Kabat, 1970)
(Figures 1, Data S1A–S1E, and Table S1) or IMGT numbering system (Figure 1B
and Data S1F) using IgBLAST software. VRC01- and NIH45-46-FWR-GLCR+
antibodies were designed to carry reverted FWRs with unreverted contactresidues based on the crystal structure of a gp120-VRC01 complex (Zhou
et al., 2010). 3BNC117- and 12A21-FWR-GLCR+-antibodies were based on
the cocrystal structures as described by Peter Kwong and colleagues (PDB
codes 4JPV and 4JPW, unpublished data). Any residue with a buried surface
area (BSA) greater than 5 A˚2 was considered significant.
Sequences of the RU01 clone (Scheid et al., 2011) were aligned using
Clustal V from the DNAstar package using PAM 250 matrix. The phylogenetic
tree was constructed using the DNAstar package, which employs a neighbor
joining method. Bootstrap values (1,000 trials, seed = 111) are as indicated
(Figure 4). Classification of neutralization potency (RU01 clone) was based
on the neutralization activity. Antibodies were grouped into potent, inter-
mediate, and poor neutralizers by taking into account the potency (IC50)
against BaL.26, DJ263.8, 6535.3, RHPA4259.7, Tro.11, PVO.4, and YU2.DG
as well as breadth (number of the tested strains neutralized) (Scheid et al.,
2011).
Cloning, Expression, and Purification of Immunoglobulins
The variable regions of all mature, FWR-GL, FWR-GLCR+, and CDR1/2-GL
antibodies were cloned into the same IgH, Igk, or Igl backbones encoding
the constant domains of the antibodies. Reversions of the FWRs were intro-
duced by overlapping PCR or by DNA synthesis (Integrated DNA Technolo-
gies). The sequence of 17b was obtained from the structure with CD4 (pdb
code 1G9M). The P61Amutation was introduced into the 3BNC60 heavy chain
gene by site-directed mutagenesis using QuikChange Site-Directed Mutagen-
esis Kit (Agilent Technologies). Because the region of the FWR3 insertion is
highly mutated and the exact location of inserted amino acids is difficult to
determine, surrounding regions from 3BNC55 and 3BNC60 were included in
each construct (Figure 5B). Likewise, the residues surrounding the engrafted
insertion in VRC01 were chosen based on the crystal structures of VRC01
and 3BNC60 (Data S1E) (Scheid et al., 2011; Zhou et al., 2010). Antibodies
were expressed and purified as previously described (Mouquet et al., 2011)
(Diskin et al., 2011).
ELISA
ELISAs for analyzing antibody binding to gp140YU2 (Figures 2, 3, and S2) was
performed as previously described (Mouquet et al., 2011).
Neutralization Assays
Neutralizing activities of mature, FWR-GL, FWR-GLCR+, and CDR1/2-GL
antibodies were determined using a TZM.bl assay as previously described
(Diskin et al., 2011; Li et al., 2005; Montefiori, 2005; Seaman et al.,
2010). Briefly, TZM.bl cells were infected with different Tier 1 to Tier 3
HIV-1-Env-pseudoviruses in the presence of serial dilutions of the anti-
bodies tested. Antibodies with neutralizing activity inhibit the infection
and a reduction of luciferase reporter gene expression can be measured
48 hr after infection. IC50 values were calculated based on the antibody
concentration that resulted in a 50% reduction of relative luminescence
units (RLU).
Surface Plasmon Resonance
Experiments were performed with a Biacore T200 (Biacore) as described
previously (Diskin et al., 2011). Briefly, YU-2 gp140 was primary amine-
coupled on CM5 chips (Biacore) at an immobilization level of 1,000 RUs. IgG
antibodies were injected over flow cells at 1 mM, at flow rates of 90 ml/min.
The sensor surface was regenerated by a 50 s injection of 10 mM glycine-
HCl pH 2.5 at a flow rate of 90 ml/min.
Crystallization and Structure of 3BNC60P61A Fab
3BNC60P61A Fab (pdb code 4GW4) was concentrated to 13.7 mg/ml in 20 mM
Tris (pH 8.0), 150 mM sodium chloride, 0.02% sodium azide (TBS) buffer.
Crystals of Fab 3BNC60P61A were obtained by mixing a protein solution at
13.7 mg/ml with 16% polyethylene glycol 6000, 0.1 M citric acid (pH 3.9),
0.15 M lithium sulfate monohydrate at 20C. For cryoprotection, crystals
were briefly soaked in mother liquor solutions supplemented with 15% and
subsequently with 30% ethylene glycol before flash cooling in liquid nitrogen.
3BNC60P61A Fab crystals grew in space group P21 (a = 64.6, b = 154.9, c =
74.2 A˚; b = 109.7) and were isomorphous to 3BNC60 Fab crystals (ScheidCell 153, 126–138, March 28, 2013 ª2013 Elsevier Inc. 135
et al., 2011). Data were indexed, integrated, and scaled using XDS (Kabsch,
2010). We used Phaser (McCoy et al., 2007) to find a molecular replacement
solution for two Fabs per asymmetric unit (chains A and H and chains B and
L for the heavy and light chains, respectively) using the 3BNC60 Fab structure
(PDB code 3RPI) as a search model after omitting residues 59–66 of the heavy
chain. Residues 59–66 were built into Fo-Fc difference electron density maps
after a few rounds of iterative refinement including noncrystallographic
symmetry restraints using Phenix (Adams et al., 2010) and Coot (Emsley
et al., 2010). The final 2.65 A˚ resolution atomic model for two 3BNC60P61A
Fabs (Rwork = 21.5%; Rfree = 25.6%) includes 12,598 protein atoms (of which
6,198 are hydrogen atoms), 199 water molecules, and 28 ligand atoms (N-
acetylglucosamine attached to Asn70 of the light chain) (Table S3). Using
the numbering established for the 3BNC60 Fab structure (Scheid et al.,
2011), the residues included in the final model are 1–132 and 141–217 of chain
H, 2–132 and 141–217 of chain A, 4–198 of chain L, and 4–199 of chain B.
The first glutamine of the 3BNC60P61A heavy chain was modeled as 5-pyrroli-
done-2-carboxylic acid. A total of 94.5%, 5.3%, and 0.3%of the residues were
in the favored, allowed and disallowed regions of the Ramachandran plot,
respectively.
Thermal Stability Comparisons
Purified 3BNC60 and 3BNC60P61A Fabs were concentrated to 10 mM in
1 mM dithiothreitol and 5 mM sodium chloride for CD studies. Far UV
wavelength scans (200 nm to 250 nm) were recorded in 1 nm increments
using an averaging time of 5 s on an Aviv 62A DS spectropolarimeter.
Both spectra showed a distinct negative signal at 218 nm, thus this wave-
length was chosen for the thermal stability comparisons. Thermostability
profiles were obtained by monitoring the CD signal at 218 nm as the temper-
ature was raised from 40C to 95C in 2C increments, allowing 1 min of
equilibration time after each temperature step and averaging the CD signal
over 30 s of measurement. Transition midpoints (Tms) were obtained by
estimating the half-point of the ellipticity change between the native and
denatured states.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, three tables, and one data file, and can be found with this article online
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